VOICE (MTN-003)

The VOICE Study – Vaginal and Oral Interventions to Control the Epidemic – was designed to evaluate the safety and effectiveness of two antiretroviral (ARV)-based approaches for preventing sexual transmission of HIV in women as well as determining which of these women are more likely to follow: applying vaginal gel (tenofovir gel) daily or taking an ARV tablet (tenofovir or Truvada^®) once a day. VOICE also includes two sub-studies: VOICE B [1] (Bone Mineral Density) and VOICE C [2] (Household and Community Factors Associated with Adherence).

The oral tenofovir and tenofovir gel arms of VOICE were dropped following interim reviews of data that determined neither product was effective in the women assigned to those study groups. Truvada continues to be evaluated. The study is expected to be completed in August 2012 and final results to be reported early 2013.

Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women [3]

Nov 25, 2011

Questions and Answers on Decision to Modify VOICE, Outcome of November 17 DSMB Review [4]

Nov 25, 2011

Please note that the information contained in the following news releases and materials may have changed since publication.

Questions and Answers on the Status of VOICE [5]

Nov 1, 2011

VOICE Fact Sheet [6]

Oct 28, 2011

Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women [7]

Sep 28, 2011

Questions and Answers on Decision to Modify VOICE, Outcome of September 16 DSMB Review [8]

Sep 28, 2011

Questions and Answers about the CDC TDF2 Study and VOICE [9]

Jul 14, 2011

VOICE Study will Continue as it Considers What Action to Take After Results of Two Trials [10]

Jul 13, 2011

Questions and Answers about Partners PrEP and VOICE [11]

Jul 13, 2011

HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,000 Women [12]

Jun 6, 2011

Microbicide Trials Network Statement on the status of VOICE Study following announcement to close the FEM-PrEP trial [13]

Apr 18 2011

Trial shows ARVs can prevent HIV in men who have sex with men, making VOICE Study in women more important than ever [14]

Nov 23, 2010

Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE [15]

Jul 19, 2010

VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe [16]

Sep 16, 2009

NIAID Press Release on start of VOICE [17]

Sep 16, 2009

HIV prevention trial of ARV-based strategies to begin next month [18]

Jul 20, 2009

VOICE Backgrounder [19]

VOICE Q&A [20]

Products Fact Sheet [21]

VOICE B (Bone Mineral Density Sub-study)

VOICE B Backgrounder [22]

VOICE B Q&A [23]

VOICE C (Community and Adherence Sub-study)

VOICE C Backgrounder [24]

VOICE C Q&A [25]

Understanding Resistance

Drug Resistance and ARV-Based Prevention Fact Sheet [26]

Drug Resistance and ARV-Based Prevention Q&A [27]

Diagrams:

Video: Drug Resistance and ARV-Based Prevention [31]

See Also

Understanding the Results of iPrEx [32]

Understanding the Results of CAPRISA 004 [33]

Pre-Exposure Prophylaxis (PrEP) Fact Sheet [34]

MTN-003 (VOICE) Study Protocol [35]

MTN-003 B (VOICE B) Study Protocol [36]

MTN-003 C (VOICE C) Study Protocol [37]